William B White Selected Research

Angiotensin Receptor Antagonists

11/2018	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.
11/2018	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
7/2017	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.
4/2016	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
1/2015	The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.
7/2014	Efficacy of azilsartan medoxomil with chlorthalidone in hypertension.
8/2012	Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
3/2012	Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension.
12/2011	Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.
7/2011	Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William B White Research Topics

Disease

92	Hypertension (High Blood Pressure) 04/2022 - 02/2002
35	Type 2 Diabetes Mellitus (MODY) 04/2022 - 05/2003
22	Heart Failure 10/2021 - 02/2002
20	Acute Coronary Syndrome 01/2021 - 10/2011
18	Myocardial Infarction 10/2021 - 02/2002
18	Stroke (Strokes) 10/2021 - 02/2002
11	Osteoarthritis 01/2018 - 04/2002
10	Arthritis (Polyarthritis) 05/2009 - 02/2002
8	Chronic Renal Insufficiency 04/2022 - 10/2003
8	Diabetes Mellitus 01/2016 - 05/2003
7	Isolated Systolic Hypertension 07/2021 - 02/2003
7	Hyperkalemia 01/2018 - 06/2005
6	Gout 01/2022 - 08/2011
6	Cardiovascular Diseases (Cardiovascular Disease) 03/2018 - 04/2003
6	Pain (Aches) 01/2018 - 08/2004
6	Essential Hypertension 12/2012 - 04/2002
5	Parkinson Disease (Parkinson's Disease) 04/2017 - 10/2002
4	Overactive Urinary Bladder (Overactive Bladder) 04/2022 - 06/2018
4	Edema (Dropsy) 04/2014 - 02/2002
4	Kidney Diseases (Kidney Disease) 06/2012 - 07/2005
3	Diabetic Nephropathies (Diabetic Nephropathy) 04/2022 - 05/2003
3	Dizziness (Lightheadedness) 01/2019 - 11/2004
3	Unstable Angina 08/2018 - 10/2013
3	Rheumatoid Arthritis 01/2018 - 07/2004
3	Orthostatic Hypotension (Postural Hypotension) 04/2017 - 10/2016
3	Coronary Disease (Coronary Heart Disease) 01/2017 - 01/2007
3	White Coat Hypertension 10/2014 - 02/2002
3	Masked Hypertension 08/2012 - 05/2008
3	Angioedema 07/2011 - 07/2002
2	Hypogonadism (Hypergonadotropic Hypogonadism) 11/2021 - 01/2021
2	Anemia 01/2021 - 12/2019
2	Headache (Headaches) 01/2019 - 12/2011
2	Hypoglycemia (Reactive Hypoglycemia) 01/2018 - 10/2013
2	Pure Autonomic Failure 04/2017 - 10/2016
2	Multiple System Atrophy 04/2017 - 10/2016

Drug/Important Bio-Agent (IBA)

34	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 02/2002
23	Angiotensin Receptor AntagonistsIBA 11/2018 - 06/2005
19	alogliptinIBA 07/2021 - 10/2011
16	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2018 - 04/2002
13	DiureticsIBA 11/2018 - 11/2002
13	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2018 - 02/2002
12	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 11/2018 - 04/2003
12	Pharmaceutical PreparationsIBA 01/2018 - 04/2003
11	azilsartan medoxomilIBA 11/2018 - 03/2011
11	Valsartan (Vals)FDA Link 04/2016 - 05/2003
10	PotassiumIBA 10/2019 - 04/2002
10	Telmisartan (Micardis)FDA Link 01/2012 - 07/2002
9	Spironolactone (Aldactone)FDA LinkGeneric 01/2021 - 05/2011
8	AldosteroneIBA 04/2022 - 05/2003
7	Mineralocorticoid Receptor AntagonistsIBA 04/2022 - 06/2005
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2011
7	Eplerenone (Inspra)FDA LinkGeneric 11/2018 - 05/2003
7	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018 - 10/2011
7	Celecoxib (Celebrex)FDA Link 01/2018 - 02/2002
7	ReninIBA 11/2013 - 07/2005
6	AmberIBA 01/2021 - 01/2018
6	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 11/2018 - 11/2002
6	Chlorthalidone (Chlortalidone)FDA LinkGeneric 11/2018 - 08/2012
6	Naproxen (Naprosyn)FDA LinkGeneric 01/2018 - 07/2004
6	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2017 - 10/2011
6	Amlodipine (Norvasc)FDA LinkGeneric 04/2014 - 07/2002
6	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 12/2008 - 04/2002
6	CalciumIBA 04/2007 - 02/2003
5	omega-Chloroacetophenone (Mace)IBA 10/2021 - 09/2013
5	patiromerIBA 01/2021 - 01/2018
5	olmesartanIBA 11/2018 - 03/2011
5	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 01/2015 - 09/2006
5	SodiumIBA 11/2013 - 09/2005
5	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2008 - 08/2003
4	Allopurinol (Remid)FDA LinkGeneric 01/2022 - 08/2011
4	Brain Natriuretic Peptide (Natrecor)FDA Link 07/2021 - 05/2015
4	Xanthine OxidaseIBA 01/2019 - 07/2012
4	ThiazidesIBA 11/2018 - 08/2012
4	1,4-dihydropyridine (dihydropyridine)IBA 01/2015 - 02/2003
4	Hormones (Hormone)IBA 06/2011 - 09/2005
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2011 - 05/2009
4	drospirenone FDA LinkGeneric 01/2008 - 09/2005
3	Febuxostat FDA Link 01/2022 - 07/2012
3	Uric Acid (Urate)IBA 01/2022 - 08/2011
3	Ibuprofen (Motrin)FDA LinkGeneric 01/2018 - 07/2004
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2018 - 10/2013
3	DroxidopaIBA 04/2017 - 10/2016
3	Renin InhibitorsIBA 03/2012 - 10/2010
3	aliskiren FDA Link 03/2012 - 10/2010
3	AngiotensinsIBA 09/2009 - 07/2005
2	testosterone undecanoateIBA 11/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2019
2	salicylhydroxamic acid (SHAM)IBA 01/2019 - 10/2014
2	Lipocalin-2IBA 01/2019 - 01/2018
2	Cystatin CIBA 01/2019 - 01/2018
2	mirabegronIBA 11/2018 - 06/2018
2	Muscarinic AntagonistsIBA 11/2018 - 06/2018
2	Adrenergic Receptors (Adrenergic Receptor)IBA 08/2018 - 06/2018
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 04/2017 - 10/2016
2	ProdrugsIBA 04/2017 - 10/2016
2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2017 - 04/2014
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2017 - 01/2016

Therapy/Procedure

55	Therapeutics 07/2021 - 11/2002
4	Denervation 01/2019 - 11/2013
4	Drug Therapy (Chemotherapy) 10/2014 - 07/2005